In this session, Dr. Suzie Bash and Kyle Frye delve into how NeuroQuant Dementia and NeuroQuant ARIA are reshaping the clinical care pathway for Alzheimer’s Disease. From enhancing early-stage memory loss evaluations to the growing acceptance of these innovative tools in clinical practice, discover the value they bring to the future of Alzheimer’s care. Learn about the advantages of using NeuroQuant in an era where disease-modifying therapies are changing treatment landscapes.

Fill out the form to watch now: